Results Of First Phase Trial Of Covaxin Have Arrived; ‘No Severe Side Effects’

New Delhi, January 2021: Two corona vaccines, Covishield, and Covaxin have been approved for emergency use in India. Covaxin has been made by Bharat Biotech and is an entirely indigenous vaccine, although people across the country are afraid of getting this vaccine.

Health workers are also raising questions about the effect of this vaccine. However, the first stage of the covaxin results has been published in the famous medical journal The Lancet. According to a report, the vaccine has enhanced the immune response without serious side effects.

The magazine stated that covaxin showed the pain of the first injection followed by headache and fever, fatigue. Suchitra Alla, joining director of India Biotech, said that covaxin is the first such vaccine in India Whose data is printed in the Lancet.

The Lancet study stated, “BBV152 code-named vaccine was well tolerated in all dose groups. It also did not reveal any serious vaccine-related events.”Experts in the biotech industry said that pain and fever are common effects displayed by every vaccine, but there has not yet been anything in covaxin that needs treatment, and it is entirely safe.

The emergency approval of the covaxin was condemned as none of its data was made public. After appearing in the Lancet, Suchitra Alla tweeted, “India’s innovation has gained international recognition.”

Similar peer review studies for Phase 2 are still awaited. Trials are on for Phase 3, as the government continues to vaccinate millions of front-line employees. While the first two phases of vaccine trials usually focus on their safety, the third stage usually determines its efficacy.

The vaccine developed in India has been prepared by Bharat Biotech in collaboration with the Medical Council (ICMR) of the Government of India and the National Institute of Virology (NIV), Pune.